Bonefos en es it fr

Bonefos Brand names, Bonefos Analogs

Bonefos Brand Names Mixture

  • No information avaliable

Bonefos Chemical_Formula

CH4Cl2O6P2

Bonefos RX_link

No information avaliable

Bonefos fda sheet

Bonefos msds (material safety sheet)

Bonefos MSDS

Bonefos Synthesis Reference

No information avaliable

Bonefos Molecular Weight

244.892 g/mol

Bonefos Melting Point

250 oC

Bonefos H2O Solubility

395 mg/L

Bonefos State

Solid

Bonefos LogP

-0.906

Bonefos Dosage Forms

Capsules; Solution

Bonefos Indication

For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.

Bonefos Pharmacology

Clodronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and tiludronate. Clodronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the clodronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Clodronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.

Bonefos Absorption

After oral administration, absorption is estimated at 1–3% of the ingested dose because of the low uptake from the gastrointestinal tract.

Bonefos side effects and Toxicity

Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients.

Bonefos Patient Information

No information avaliable

Bonefos Organisms Affected

Humans and other mammals